Hird Amanda E, Chow Edward, Ehrlich Lisa, Probyn Linda, Sinclair Emily, Yip Darwin, Ko Yoo-Joung
Rapid Response Radiotherapy Program, Radiation Oncology, Odette Cancer Centre, University of Toronto, Toronto, Ontario, Canada.
J Palliat Med. 2008 Oct;11(8):1156-61. doi: 10.1089/jpm.2008.9846.
Renal cell carcinoma (RCC) represents approximately 3% of all adult cancers and is more common in males. Systemic treatment for RCC has improved following the introduction of sunitinib. Bone metastases are present in up to 50% of RCC patients. We report a case of rapid improvement in metastatic bone lesions, recorded by nuclear bone scan, in a male patient receiving localized palliative radiotherapy in addition to systemic sunitinib and zoledronic acid. Concurrently, quality of life and performance status improved dramatically. Although we are unsure of the exact mechanism for such rapid improvement in metastatic bone lesions, the swiftness this improvement deserves reporting.
肾细胞癌(RCC)约占所有成人癌症的3%,在男性中更为常见。随着舒尼替尼的引入,RCC的全身治疗有了改善。高达50%的RCC患者会出现骨转移。我们报告了一例男性患者,在接受全身舒尼替尼和唑来膦酸治疗的同时接受局部姑息性放疗,其转移性骨病变经核素骨扫描显示迅速改善。同时,生活质量和体能状态也显著改善。尽管我们不确定转移性骨病变如此迅速改善的确切机制,但这种改善的迅速程度值得报告。